drugset / Trial / NCT07833202
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, positive controlled, open-Label and multicenter phase III study, to evaluate the efficacy and safety of Sosimerasib in combination with IN10018 versus anti-PD-1 monoclonal antibody in combination with carboplatin and pemetrexed as the first-line treatment for the locally advanced or metastatic non-squamous non-small cell lung cancer with KRAS G12C mutation.
Timeline
- Start
- 2026-10
- Primary completion
- 2029-04
- Completion
- 2030-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Subject | Ifebemtinib | Small molecule | — | Oral |
| Comparator | Pemetrexed | Small molecule | — | Intravenous |
| Subject | Sosimerasib | Unknown | — | Oral |
| Comparator | Tislelizumab | Monoclonal antibody | — | Intravenous |